论文部分内容阅读
目的探讨乙型肝炎基因分型与阿德福韦酯疗效相关性。方法选择2010年1月-2012年12月使用阿德福韦酯进行治疗的350例乙型肝炎患者作为研究对象,根据患者的基因分型将其分为B、C两组,其中B组患者271例,男183例,女88例;C组患者79例,男53例,女26例。对患者治疗前及治疗后12、24、48、96周时HBV DNA及乙型肝炎e抗原(HBeAg)阳性患者e抗原转阴的情况进行观察分析。结果经过治疗之后B、C型乙型肝炎患者的HBV DNA转阴慢,两组患者在治疗后第12、24、48、96周相比较差异均无统计学意义(均P>0.05);其中乙型肝炎HbeAg阳性病例血清转换方面,经统计分析两组患者从12周到第96周相比较差异均无统计学意义(均P>0.05),血清转换较慢,而且会随着时间的延长转阴率可提高。结论阿德福韦酯能够对HBV复制产生明显的抑制作用,促进患者炎症消退和HBeAg血清转换。阿德福韦酯对于B型及C型乙型肝炎感染患者进行抗病毒治疗,临床疗效没有明显影响。
Objective To investigate the relationship between hepatitis B genotyping and adefovir dipivoxil efficacy. Methods A total of 350 hepatitis B patients treated with adefovir dipivoxil from January 2010 to December 2012 were selected as study subjects and divided into groups B and C according to their genotyping. Patients in group B 271 cases, 183 males and 88 females; Group C 79 patients, 53 males and 26 females. Patients before treatment and after treatment, 12,24,48,96 weeks HBV DNA and hepatitis B e antigen (HBeAg) -positive patients with e antigen overcast were observed and analyzed. Results After treatment, the HBV DNA in patients with chronic hepatitis B and C was slowed down. There was no significant difference between the two groups in the 12th, 24th, 48th and 96th week after treatment (all P> 0.05) Hepatitis B HBeAg-positive cases of seroconversion, the statistical analysis of two groups of patients from 12 weeks to 96 weeks, there was no significant difference (all P> 0.05), seroconversion slow, and will change with the extension of time Yin rate can be increased. Conclusion Adefovir dipivoxil can significantly inhibit HBV replication and promote the regression of inflammation and HBeAg seroconversion in patients. Adefovir dipivoxil treatment for patients with type B and C hepatitis B virus antiviral therapy, no significant clinical effect.